Back to search

Article

Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner

2019-11-20

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Objective</h4> Eicosapentaenoic acid (EPA) has recently garnered strong attention given the success of the REDUCE-IT trial, which overturned previous conclusions on EPA and led to its FDA approval for lowering cardiovascular disease risk. Therefore, there is a need to study EPA for cardiometabolic risk factors. Here we focused on EPA’s preventative role on hyperglycemia and hyperinsulinemia...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3a2f4124-5894-5355-8881-ed7730fdb04d
DOI
10.1101/848093
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic mannerDOI 10.1101/848093
Select a neighboring publication to make it the new centre.